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Malaria has long been a major cause of mortality within the Armed Forces 
(AF), historically inflicting heavier casualties than combat injuries [1]. Advances 
have been made in preventing malaria transmission; nonetheless, military personnel 
deploying to areas with malaria continue to be vulnerable to the disease.  
Antimalarial drug resistance is a leading challenge in the control of malaria. 
Chloroquine resistant strains of malaria, such as Plasmodium falciparum, are 
responsible for most human malaria cases and can be found across several regions of 
Southeast Asia, South America, and Africa [2]. There are currently three licensed 
anti-malarial drugs against chloroquine resistant Plasmodium falciparum malaria: 
mefloquine (trade name: Lariam©), doxycycline, and a combination of atovaquone 
and proguanil (trade name: Malarone©). These agents differ in their active 
ingredients, side effects, dosages, cost and contraindications, and as with any drug, 
need to be prescribed appropriately given an individual’s medical history. For 
example, to minimise risk of adverse reactions mefloquine must not be prescribed for 
patients with active or history of psychiatric disorders [3]. However, it is important to 
recognise that there is no single anti-malarial that is 100% effective against all the 
different strains of malaria and all three antimalarials can cause adverse effects [4].  
 Mefloquine has received considerable media attention following incidents 
involving US soldiers committing acts of violence while taking the drug [5]. Formal 
inquests have since refuted that mefloquine was the cause, with there being no 
evidence to support a causal link between taking the drug and the violent responses 
[6]. Nonetheless, as a result of the media interest, the use of mefloquine within 
military settings is now somewhat controversial [7].  
Use of mefloquine in the AF 
 2 
Many international AF currently include mefloquine in their 
chemoprophylactic treatments, not specified as agents of last resort, including the 
Irish and Canadian AF. Presently, the UK Ministry of Defence (MoD) supports the 
prescription of mefloquine to AF personnel where it is deemed to be the appropriate 
medication [6]. Counter to this stance, the US military and Australian Defence Forces 
(ADF)[8] restrict mefloquine’s use to a third-line drug, only prescribed when there are 
contraindications to other antimalarials. The drug is banned altogether by certain US 
military units (e.g. Special Forces, aviators and divers) [9]. 
Responses to mefloquine in military personnel 
Some evidence of potential adverse mefloquine effects stems from a study 
which examined Swedish soldiers prescribed mefloquine or another antimalarial [10]. 
Adverse effects, including neuropsychological effects, were more commonly reported 
in the mefloquine group (see Table 1). Similarly, in a study of 4,123 Italian AF 
regulars, 21.2% (n= 875) of those prescribed mefloquine reported adverse events. 
However, no serious adverse events were reported, and authors concluded ‘good 
tolerability of mefloquine in the military’[11]. In US troops, deployed personnel 
prescribed mefloquine were significantly more likely to experience anxiety, while 
non-deployed personnel prescribed mefloquine were significantly more likely to 
experience symptoms of posttraumatic stress disorder (PTSD) [12]. This difference in 
non-deployed personnel may potentially reflect a healthy warrior effect [13].  
 Nevertheless, several studies have reported few or no adverse responses to 
mefloquine in other military samples. In the British AF, research found that of 486 
personnel prescribed mefloquine only 11 individuals reported adverse side effects [6]. 
Furthermore, a study of UK personnel in East Africa [14] found mefloquine was no 
more problematic with respect to side effects than the chloroquine/proguanil regime. 
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However, the small numbers of participants in these studies may limit the 
generalisability of the findings. In the ADF, of 1,157 participants, only 6.5% (n=75) 
of personnel taking mefloquine withdrew from the trial because of adverse responses 
to the drug and the rate of adverse side effect reporting was similar across 
antimalarials [15]. Finally, Defence Statistics found that between 2009-2010, UK AF 
personnel prescribed mefloquine or a different antimalarial were equally likely to be 
assessed as having a mental health disorder. However, Defence Statistics did not have 
data available to allow them to determine whether the reason for assessment was due 
to the prescription of an antimalarial drug or other potentially confounding factors. 
For example, this time period corresponds with the highest number of casualties the 
UK AF sustained in Afghanistan [16].  
Factors which may influence the experience of mefloquine side effects  
First, the military environment can expose individuals to challenging 
conditions that may cause some symptoms similar to the side effects of mefloquine. 
For instance, the stress of deployment, sleep deprivation and high intensity operations 
could lead to increased anxiety and sleep disturbances which are known side effects 
of the drug. Secondly, it is possible that mental health-related stigma or fears of 
falling short of the medical criteria that deems personnel fit to deploy [17] may 
contribute to under-reporting of mefloquine side effects. This reluctance to present 
prevents individuals being switched to an alternative medication and inhibits the 
medical community’s understanding of the true impact of the drug within this 
population. Lastly, there is evidence in civilian populations of increased risk of 
psychiatric illness in female mefloquine users [18] and little research has been done to 
identify if this might place female service personnel at increased risk.  
Directions for future research  
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There is no clear evidence that mefloquine use by military personnel presents 
a disproportionate risk to their mental health. Nonetheless, several shortfalls in the 
current literature exist, including a lack of detail on exactly which side effects are 
being described, highlighting a need for future studies with a more transparent 
methodology. There are many distinct differences between military and civilian 
personnel (e.g. underlying fitness, greater exposure to hostile environments; sleep 
deprivation; stress) and further investigation of how these factors may contribute 
towards tolerance of antimalarials seems warranted.  
Currently, mefloquine remains one of the World Health Organisation’s 
essential drugs [19], and no national licensing authority has withdrawn mefloquine 
based on toxicity [3]. However, it is clear that the prescription of mefloquine to 
patients with a significant psychiatric history is contraindicated. Negative media 
attention and anecdotal evidence may also have contributed towards concerns 
regarding the harmful effects of mefloquine on mental health, especially in military 
personnel. Such misinformation may in itself heighten awareness of subjective 
symptoms, leading to increased reporting of side effects. There is evidence from 
military studies of vaccine administration that military personnel who perceived that 
they might experience side effects were more likely to do so [20]. We suggest that 
whilst more research is warranted, sensible and evidence-based reporting of the risks 
of mefloquine and risks of malaria should be readily available to ensure that troops 
who are prescribed the medication are not unduly worried whilst the medical staff 
who prescribe it remain alert to its potential to cause side effects.  
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Table 1 
Included studies sample characteristics, antimalarials administered and outcomes 
Study Military Deployment 
location 
N Anti-malarial 
administered 
Outcome 
Andersson et 
al., 2008 
Sweden Liberia 1,170 Mefloquine, 
atovaquone/proguanil 
Adverse events reported in 57% of the mefloquine group vs 34% 
in the atovaquone/proguanil group.  
Eick-Cost et 
al., 2017 
United 
States 
Afghanistan, Iraq, 
Africa or other 
367,840 Mefloquine, 
doxycycline, 
atovaquone/proguanil 
Deployed mefloquine group more likely to experience anxiety 
compared with doxycycline recipients (IRR= 1.12, 95% CI 1.01-
1.24). Non-deployed mefloquine group more likely to experience 
PTSD compared to atovaquine/proguanil recipients (IRR= 1.83, 
95% CI 1.07-3.14) 
Peragallo et 
al., 2014 
Italy Afghanistan 4,123 Mefloquine Adverse events reported by 21.2% of personnel. No serious 
adverse events reported.   
Ministry of 
Defence, 2017 
United 
Kingdom 
Afghanistan 486 Mefloquine 2.46% of personnel experienced adverse reactions. 1.8% of 
personnel required mefloquine to be withdrawn.  
Croft et al., 
1997 
United 
Kingdom 
East Africa 624 Mefloquine, 
chloroquine-
proguanil 
Incidence of adverse events was not significantly different 
between mefloquine and chloroquine-proguanil groups (OR 
0.96; 95% CI 0.63-1.47). No serious adverse events reported. 
Kitchener et 
al., 2005 
Australia East Timor 1,157 Mefloquine, 
doxycycline 
57% of personnel prescribed mefloquine reported one or more 
adverse events vs 56% of doxycycline group.  
Defence 
Statistics, 2016 
United 
Kingdom 
Kenya, Congo, 
Guinea, Ghana, 
Sierra Leone 
116,704 Mefloquine, other 
antimalarial drug 
10.0% of mefloquine group and 9.8% of other antimalarial drugs 
group assessed as having a mental health disorder in 2009-2010. 
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Note. IRR= incidence rate ratio. N= total number of participants. CI = confidence interval. PTSD = posttraumatic stress disorder. OR= odds 
ratio.  
  
